Link between the Farmacotherapeutisch Kompas and the Medicines Information Bank

The official product information of the Medicines Evaluation Board (MEB) has been made directly accessible via the Farmacotherapeutisch Kompas (FK). The FK also provides direct access to the information about ‘reported adverse events’ at the Netherlands Pharmacovigilance Centre Lareb. This is an expansion of the information made available through the FK.

A prescriber has to determine the right pharmacotherapy in a relatively short period of time frequently consulting the FK for objective and reliable information in the process.

The most important information is contained in the preparation texts of the FK. To view comprehensive product information, click on the "Officiële productinformatie CBG/EMA" link in the preparation text. This link takes you to the MEB’s Medicines Information Bank. This data bank contains up-to-date product information (SmPC), the package leaflet for patients and the public assessment report (PAR).

The MEB is committed to providing correct and up-to-date information in a user-friendly way. You can contact the MEB if you have suggestions on how to further improve our information.

Connecting the MEB, Lareb and the FK in this way is in line with the objective outlined in the MEB’s Strategic Business Plan 2014-2018 for promoting the proper use of medicinal products by making pharmacotherapeutic information available to healthcare providers.